MAZZEO, Anna
 Distribuzione geografica
Continente #
EU - Europa 13.255
NA - Nord America 11.049
AS - Asia 7.823
SA - Sud America 2.651
AF - Africa 242
Continente sconosciuto - Info sul continente non disponibili 15
OC - Oceania 13
Totale 35.048
Nazione #
US - Stati Uniti d'America 10.784
RU - Federazione Russa 6.529
SG - Singapore 3.656
BR - Brasile 2.252
CN - Cina 2.008
IE - Irlanda 1.706
SE - Svezia 1.167
IT - Italia 990
HK - Hong Kong 785
DE - Germania 712
FI - Finlandia 480
FR - Francia 469
VN - Vietnam 435
UA - Ucraina 405
PL - Polonia 286
GB - Regno Unito 237
IN - India 219
AR - Argentina 154
BD - Bangladesh 141
CA - Canada 102
MX - Messico 93
TR - Turchia 81
ZA - Sudafrica 67
EC - Ecuador 66
IQ - Iraq 65
ID - Indonesia 60
NL - Olanda 55
MA - Marocco 51
UZ - Uzbekistan 47
BE - Belgio 45
CO - Colombia 45
PK - Pakistan 45
JP - Giappone 44
AT - Austria 39
VE - Venezuela 36
CL - Cile 33
ES - Italia 33
CI - Costa d'Avorio 29
PY - Paraguay 25
KE - Kenya 24
PE - Perù 21
AZ - Azerbaigian 20
PH - Filippine 20
SA - Arabia Saudita 19
TN - Tunisia 19
IL - Israele 18
LT - Lituania 18
NP - Nepal 17
AE - Emirati Arabi Uniti 14
CZ - Repubblica Ceca 14
EU - Europa 14
JO - Giordania 14
KZ - Kazakistan 14
AL - Albania 13
DZ - Algeria 12
JM - Giamaica 12
DO - Repubblica Dominicana 11
MY - Malesia 11
HN - Honduras 10
KR - Corea 10
RO - Romania 10
TH - Thailandia 10
AU - Australia 9
BO - Bolivia 9
EG - Egitto 9
KG - Kirghizistan 9
LB - Libano 9
UY - Uruguay 9
RS - Serbia 8
CR - Costa Rica 7
IR - Iran 7
PS - Palestinian Territory 7
GT - Guatemala 6
NI - Nicaragua 6
PA - Panama 6
SK - Slovacchia (Repubblica Slovacca) 6
GA - Gabon 5
GR - Grecia 5
LK - Sri Lanka 5
OM - Oman 5
SN - Senegal 5
AM - Armenia 4
BH - Bahrain 4
CH - Svizzera 4
ET - Etiopia 4
KW - Kuwait 4
LA - Repubblica Popolare Democratica del Laos 4
PT - Portogallo 4
AO - Angola 3
BW - Botswana 3
NZ - Nuova Zelanda 3
PR - Porto Rico 3
SY - Repubblica araba siriana 3
BA - Bosnia-Erzegovina 2
BN - Brunei Darussalam 2
DM - Dominica 2
HR - Croazia 2
HU - Ungheria 2
LU - Lussemburgo 2
LV - Lettonia 2
Totale 35.010
Città #
Moscow 2.144
Ashburn 1.770
Dublin 1.700
Singapore 1.557
Dallas 1.365
Chandler 1.110
Jacksonville 859
Hong Kong 781
Nyköping 752
Beijing 693
San Jose 466
The Dalles 371
Messina 345
Princeton 299
Munich 292
Warsaw 278
Lauterbourg 277
Medford 270
Los Angeles 261
Cambridge 232
Des Moines 218
Ann Arbor 181
Dearborn 175
São Paulo 156
Ho Chi Minh City 155
Buffalo 149
Helsinki 149
New York 148
Council Bluffs 116
Boardman 101
Tianjin 97
Wilmington 78
Guangzhou 75
Turku 75
Hanoi 71
Rio de Janeiro 70
Orem 68
Redondo Beach 67
San Mateo 67
Jinan 65
Belo Horizonte 60
Shenyang 60
Santa Clara 58
Bremen 52
Pune 47
Woodbridge 46
Brasília 45
Tashkent 44
Hyderabad 43
Chennai 42
Frankfurt am Main 42
Houston 42
Lancaster 41
Shanghai 39
Nanjing 36
Tokyo 36
Curitiba 35
Brooklyn 34
Seattle 33
Shenzhen 33
Montreal 32
Ningbo 32
Nuremberg 32
Porto Alegre 32
Chicago 31
Hebei 31
Johannesburg 31
London 31
Brussels 30
San Francisco 30
Zhengzhou 30
Abidjan 29
Hangzhou 29
Rome 28
Mexico City 27
Baghdad 26
Guayaquil 26
Mumbai 26
Salvador 26
Boston 25
Haikou 25
Lappeenranta 25
Amsterdam 24
Denver 24
Campinas 23
Catania 23
Istanbul 23
Milan 23
Nairobi 23
Jakarta 22
Palermo 22
Quito 22
Taizhou 22
Da Nang 21
Dhaka 21
Guarulhos 21
Manchester 21
Norwalk 21
Ribeirão Preto 21
Vienna 21
Totale 20.003
Nome #
A NOVEL SERUM MICRORNA SIGNATURE TO SCREEN TRANSTHYRETIN-RELATED FAMILIAL AMYLOID POLYNEUROPATHY 366
6MWT performance correlates with peripheral neuropathy but not with cardiac involvement in patients with hereditary transthyretin amyloidosis (hATTR) 329
Psychosocial impact of presymptomatic genetic testing for amyloidotic polyneuropathy 285
Value of 99mTc-DPD scintigraphy as early diagnostic modality in familial amyloidotic polyneuropathy. 274
Diagnostic utility of Sudoscan for detecting Bortezomib-induced painful neuropathy 253
A CMT1A PATIENT WITH PAINFUL AND DISABLING SYMPTOMS: FAST RECOVERY AFTER IVIG TREATMENT. 250
Clinical and pathological features of focal myositis 248
HATTR italian registry: preliminary data from the collaborative network of telethon GUP 15010 study 248
Responsiveness of clinical outcome measures in Charcot-Marie-Tooth disease 246
Etanercept for psoriasis and psoriatic arthritis in a patient with Charcot-Marie-Tooth disease 244
A Nouvel serum MicroRNA signature to screen ATTR 228
2D Feature Strain Echocardiography in patients with transthyretin familial amyloid plyneuropathy and diffuse cardiac 99mTc-DPD accumulation 221
A multicenter, randomized, double-blind, placebo-controlled trial of long-term ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL): the study protocol 219
Circulating microRNAs Profile in Patients With Transthyretin Variant Amyloidosis 216
Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area 212
A family with autosomal dominant mutilating neuropathy not linked to either Charcot-Marie-Tooth disease type 2B (CMT2B) or hereditary sensory neuropathy type I (HSN I) loci 211
Advances in Treatment of ATTRv Amyloidosis: State of the Art and Future Prospects 198
A novel mutation in KIF5A gene causing hereditary spastic paraplegia with axonal neuropathy. 193
Transthyretin-Related Familial Amyloid Polyneuropathy (TTR-FAP): A Single-Center Experience in Sicily, an Italian Endemic Area 193
"Dropped- head" syndrome due to isolated myositis of neck extensor muscles: MRI findings 191
Behaviour of vinculin and talin in perineurial cells in healthy subjects and in subjects affected by diabteic neuropathy 190
ATTRv amyloidosis Italian Registry: clinical and epidemiological data 189
Comparison Between 99mTc-Diphosphonate Imaging and MRI With Late Gadolinium Enhancement in Evaluating Cardiac Involvement in Patients With Transthyretin Familial Amyloid Polyneuropathy 182
ANT1 is reduced in sporadic inclusion body myositis. 177
Parenteral nutrition improves nutritional status, autonomic symptoms and quality of life in transthyretin amyloid polyneuropathy 176
Chronic inflammatory demyelinating polyradiculoneuropathy: can a diagnosis be made in patients not fulfilling electrodiagnostic criteria? 174
Diagnosis of cardiac amyloid transthyretin (ATTR) amyloidosis by early (soft tissue) phase [99mTc]Tc-DPD whole body scan: comparison with late (bone) phase imaging 172
Cardiac longitudinal and radial strain is impaired in TTR-FAP: a magnetic resonance and 2-dimensional strain echocardiography study. 171
Charcot-Marie-Tooth 2F: phenotypic presentation of the Arg136Leu HSP27 mutation in a multigenerational family 170
ANT1 expression and RAGE-NF-kB pathway in sporadic inclusion body myositis. 169
A novel Cx32 mutation with unusual phenotype. 169
NfL as a biomarker in ATTRv amyloidosis: potential and limitations 168
Cardiac 99mTc-DPD uptake in subjects with Glu89Gln transthyretin gene mutation: is it the earliest sign of disease development? 168
Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 1: peripheral neuropathies 167
Asymptomatic hyperCKemia in a case of Danon disease due to a missense mutation in Lamp-2 gene 166
Activation of nuclear factor-kappa B in inflammatory myopathies and Duchenne muscular dystrophy 166
Is overwork weakness relevant in Charcot-Marie-Tooth disease? 166
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study 163
Myopathy as the persistently isolated symptomatology of primary autoimmune hypothyroidism 162
Coinvolgimento Cardiaco in Pazienti con Polineuropatia Amiloidotica Familiare: Dimostrazione Precoce con Cardio-Rm 162
Parenteral nutrition improves nutritional status, autonomic symptoms and qol in patients with TTR-FAP 161
Cardiac longitudinal and radial strain is impaired in TTR-FAP: a magnetic resonance and 2-dimensional strain echocardiography study 159
A NOVEL MUTATION IN KIF5A GENE CAUSING HEREDITARY SPASTIC PARAPLEGIA WITH AXONAL NEUROPATHY; 158
Are novel outcome measures for Charcot–Marie–Tooth disease sensitive to change? The 6-minute walk test and StepWatch™ Activity Monitor in a 12-month longitudinal study 158
Contactin 1, a Potential New Antigen Target in Membranous Nephropathy: A Case Report 158
Amyloid myopathy presenting with rhabdomyolysis: Evidence of complement activation 157
Cardiac longitudinal and radial strain is impaired in TTR-FAP: a magnetic resonance and 2-dimensional strain echocardiography study 156
Anxiety and depression in Charcot-Marie-Tooth disease: data from the Italian CMT national registry 156
Activation of nuclear factor-κB in inflammatory myopathies and Duchenne muscular dystrophy 154
Acquired idiopathic generalized anhidrosis: a case report 154
Dolori muscolari, deficit di forza e/o disturbi sensitivi 154
Prevalence and diagnostic value of extra-left ventricle echocardiographic findings in transthyretin-related cardiac amyloidosis 153
Cardiac involvement in transthyretin familial amyloid polyneuropathy - comparison between 99mTc-DPD SPECT and magnetic resonance imaging 152
Acquired idiopathic generalized anhidrosis: a case report 151
Novel outcome measures for Charcot-Marie-Tooth disease: Validation and reliability of the 6-min walk test and StepWatch™ Activity Monitor and identification of the walking features related to higher quality of life 151
A novel Cx32 mutation with unusual phenotype 149
Expression of transglutaminase 2 does not differentiate focal myositis from generalized inflammatory myopathies 148
Correlation between semiquantitative analysis of 99mTc-DPD scintigraphy and clinical scores in patients with familial amyloidotic polyneuropathy 148
Charcot-Marie-Tooth disease: experience from a large Italian tertiary neuromuscular center 148
A novel CX32 mutation with unusual phenotype 147
ANT1 expression and RAGE-NF-kB pathway in sporadic inclusion body myositis 147
Charcot-Marie-Tooth type X: unusual phenotype of a novel CX32 mutation 145
Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial 145
Activation and localization of transcription factor NF-KB in peripheral neuropathies of different origin. 145
Cardiac longitudinal and radial strain is impaired in TTR-FAP: a magnetic resonance and 2-dimensional strain echocardiography study. 144
Mid-basal left ventricular longitudinal dysfunction as a prognostic marker in mutated transthyretin-related cardiac amyloidosis 144
Clinical and genotype characteristics and symptom migration in patients with mixed phenotype transthyretin amyloidosis from the transthyretin amyloidosis outcomes survey 142
Sport activity in Charcot-Marie-Tooth disease: A case study of a Paralympic swimmer 142
Atrial function in cardiac amyloidosis: a 2d-strain echocardiography and cardiac MRI study 141
Bilateral symmetrical peroneal neuropathy: rapid recovery after IVIG. 141
Amyloid myopathy presenting with rhabdomyolysis: evidence of complement activation. 140
Multifocal motor neuropathy and asymptomatic Hashimoto's thyroiditis: first report of an association 139
Cardiac Involvement in Patients with Family Amyloid Polyneuropathy: Early Demostration with Cardiac Magnetic Resonance 138
Nerve conduction velocity in CMT1A: what else can we tell? 138
Bilateral symmetrical peroneal neuropathy: rapid recovery after IVIG 137
Amyloid myopathy presenting with rhabdomyolysis 137
Atypical rat cerebellar immunoreactivity in a patient with familial amyloid polyneuropathy. 136
LOCALIZATION OF VINCULIN AND TALIN AT PERINEURIAL CELLS OF HUMAN SURAL NERVE 135
AUTONOMIC DYSFUNCTION AND HEART INVOLVEMENT IN TRANSTHYRETIN FAMILIAL AMYLOIDOTIC POLYNEUROPATHY 135
Espressione di ANT1 e attivazione della via RAGE-NF-kB nella miosite a corpi inclusi. 134
Amyloid myopathy presenting with rhabdomyolysis. 133
Amyloid myopathy presenting with rhabdomyolisis: evidence of complement activation. 133
Behaviour of Vinculin and Talin in Perineurial Cells in Healthy Subjects and in Subjects Affected by Diabetic Neuropathy. 133
Quantitative comparison between amyloid deposition detected by 99mTC-diphosphonate imaging and myocardial deformation evaluated by strain echocardiography in transthyretin-related cardiac amyloidosis 131
Atypical rat cerebellar immunoreactivity in a patient with familial amyloid polyneuropathy. 130
Facial onset sensory motor neuronopathy: not always a slowly progressive disorder. 130
Early Impairment of Right Ventricular Morphology and Function in Transthyretin-Related Cardiac Amyloidosis 130
Autoimmune polyglandular disease (APECED) and mutineuropathy: a case report 129
Usefulness of Combining Electrocardiographic and Echocardiographic Findings and Brain Natriuretic Peptide in Early Detection of Cardiac Amyloidosis in Subjects With Transthyretin Gene Mutation 129
Monitoring safety and effectiveness of tafamidis in transthyretin amyloidosis in italy. A 3-year longitudinal multicenter study in a non-endemic area. 129
CMT subtypes in a cohort of italian patients enrolled at Messina neuromuscular centre since 1994 to 2014. 129
Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS). 128
MRI of cardiac involvement in transthyretin familial amyloid polyneuropathy 127
Acquired idiopathic generalized anhidrosis: a case report. 127
A novel CX32 mutation with unusual phenotype 127
Dp116, talin, vinculin and vimentin immunoreactivities following nerve transection 126
Considerable post-partum worsening in a patient with CMT2E 126
Phenotypic variability of TTR Val122Ile mutation: a Caucasian patient with axonal neuropathy and normal heart 126
Late-onset mitochondrial neuromyopathy: an age-related phenomenon ? 125
Acquired idiopathic generalized anhidrosis: a case report. 125
Totale 16.702
Categoria #
all - tutte 121.301
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 121.301


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202167 0 0 0 0 0 0 0 0 0 0 0 67
2021/20221.675 25 188 33 85 97 15 135 86 41 95 204 671
2022/20234.505 387 389 219 308 317 415 46 250 2.017 22 102 33
2023/20241.090 79 184 92 73 94 251 26 69 5 72 13 132
2024/20256.750 130 61 95 361 284 315 307 1.288 1.529 336 827 1.217
2025/202616.937 802 1.259 1.504 1.320 1.374 3.566 1.956 1.945 1.928 724 303 256
Totale 35.634